Physician profile
Haroon Khalid
NPI 1326200767
$6,511.27
in general payments reported to CMS, 2019-2025
28 companies · $1,090 in 2025
The $1,090 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $449 · 2020: $361 · 2021: $1,164 · 2022: $1,483 · 2023: $1,339 · 2024: $625 · 2025: $1,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,047 · Education: $6.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,047.49 |
| Education | $6.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,110.75 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $1,031.21 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $477.05 | 2022-2025 | Dupixent |
| Genzyme Corporation | $405.46 | 2019-2025 | |
| Genentech USA, INC. | $366.00 | 2019-2025 | Xolair |
| Optinose US, INC. | $317.59 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $303.69 | 2019-2023 | Spiriva Respimat |
| Takeda Pharmaceuticals U.S.A., INC. | $185.71 | 2020-2024 | Takhzyro |
| Amgen INC. | $183.30 | 2022-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $172.81 | 2019-2025 | |
| Kaleo, INC. | $166.97 | 2020-2023 | Auvi-Q |
| Sanofi-Aventis U.S. LLC | $116.43 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $111.42 | 2019-2022 | |
| Pfizer INC. | $95.52 | 2021-2025 | |
| Csl Behring | $87.34 | 2019-2023 | Hizentra |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $75.36 | 2022 | |
| Alk-Abello, INC | $47.32 | 2020-2022 | |
| Ars Pharmaceuticals Operations, INC. | $43.41 | 2025 | Neffy |
| Leo Pharma INC. | $37.93 | 2022 | |
| Shire North American Group INC | $28.74 | 2019 | |
| Hospira, INC. | $25.04 | 2025 | |
| Lilly USA, LLC | $23.19 | 2025 | Ebglyss |
| Aimmune Therapeutics, INC. | $19.74 | 2022 | |
| Gc Biopharma USA, INC. | $18.65 | 2025 | Alyglo |
| Blueprint Medicines Corporation | $16.81 | 2025 | Ayvakit |
| Merck Sharp & Dohme LLC | $15.49 | 2021 | |
| Phadia US INC. | $15.05 | 2021 | |
| Uswm, LLC | $13.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haroon Khalid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.